WorldCat Identities

Fox Chase Cancer Center

Works: 111 works in 241 publications in 1 language and 445 library holdings
Genres: Periodicals  Conference proceedings 
Classifications: RC267, 616
Publication Timeline
Most widely held works by Fox Chase Cancer Center
Scientific report( )

in English and held by 186 WorldCat member libraries worldwide

Institute for cancer research : twenty-ninth scientific report ; and, American Oncologic Hospital : first scientific report( Book )

1 edition published in 1984 in English and held by 8 WorldCat member libraries worldwide

Fox Chase Cancer Center : Scientific Report, 1996 by Fox Chase Cancer Center( Book )

2 editions published between 1996 and 1997 in English and held by 6 WorldCat member libraries worldwide

Scientific report by Fox Chase Cancer Center( Book )

2 editions published in 1986 in English and held by 6 WorldCat member libraries worldwide

Fox Chase Cancer Center : Scientific Report, 1998 basic science, medical science, population science by Fox Chase Cancer Center( Book )

2 editions published between 1998 and 1999 in English and held by 5 WorldCat member libraries worldwide

Scientific report by Pa.) Institute for Cancer Research (Philadelphia( Book )

1 edition published in 1986 in English and held by 4 WorldCat member libraries worldwide

Identification of Two Candidate Tumor Suppressor Genes on Chromosome 17p13.3: Assessment of Their Roles in Breast and Ovarian Carcinogenesis( Book )

5 editions published between 1997 and 2001 in English and held by 3 WorldCat member libraries worldwide

OVCA1 and OVCA2 were first identified by us as candidate tumor suppressor genes, due to the fact that they map to a critical region of frequent allelic loss in breast and ovarian cancer at l7p13.3. Our studies have shown that OVCA1 is mutated in some tumor cell lines, and its protein levels are decreased or lost in nearly 40% of breast and ovarian adenocarcinomas, while OVCA2 appears to be unaffected. Expression of low levels of exogenous OVCA1 results in dramatic growth suppression and decreased levels of cyclin D1. We used a yeast-2-hybrid screen to identify OVCA1-associating proteins. One such protein, RBM8, was identified. Amino acid sequence indicates that RBM8 is a new member of an RNA-binding motif (RBM) family which is highly conserved evolutionarily. RBM8, also know as Y14 has been shown to be a shuttling protein that preferentially associates with spliced mRNA in the nucleus and remains associated with newly exported mRNA in the cytoplasm. Mutational analysis revealed no somatic mutations in ovarian tumor however, our current studies suggest that RBM8 is involved in mRNA export and that its levels may be significantly upregulated in most transformed cells. Overall, our studies indicate that altered expression and/or post-translational modifications of OVCA1 is associated with the development of breast and ovarian tumors and suggest a potentially new mechanism for the inactivation of tumor suppressors in cancer
Establishment of the Fox Chase Network Breast Cancer Risk Registry( Book )

6 editions published between 1995 and 1998 in English and held by 2 WorldCat member libraries worldwide

The wealth of research regarding the complex interaction of the genetic, biologic and environmental factors associated with breast carcinogenesis offers promise towards better understanding of breast cancer. The progress in molecular genetics provides us with opportunities to expand our knowledge about modifiable causes of breast cancer. The development of the Fox Chase Cancer Center Breast Cancer Risk Registry was proposed to facilitate research in the epidemiologic and genetic predictors of disease and permitted evaluation of the effectiveness of new risk counseling, surveillance and prevention strategies. Staff training, sharing resources and administrative support were critical components to assist the community hospital to develop a high-risk program. Formal and on-going inservice training in cancer genetics, breast cancer risk and genetic educational resources, telephone consultation, DNA blood collection procedures, and continuous monitoring were necessary for implementation and coordination of a community-based risk registry. The establishment of an Advisory Panel helped address additional issues of informed consent, reimbursement, and community-based counseling strategies. This project demonstrates that with appropriate resources and support, it is feasible to establish a registry for individuals at high risk for breast cancer and further our understanding of the genetic and epidemiologic basis of the disease
Antibody - Pretargeted Cytokine Therapy of Cancer( )

4 editions published between 2000 and 2003 in English and held by 0 WorldCat member libraries worldwide

We hypothesize that the selective accumulation of systemically administered cytokines at tumor sites can alter tumor microenvironments to favor the induction of anti-tumor immune responses. We further hypothesize that this can be accomplished by pre-targeting tumors with antibody-streptavidin immunoconjugates and then administering biotinylated cytokines. The purpose of this research program is to identify antibody-pretargeted cytokine therapy strategies that lead to tumor-selective cytokine accumulation the development of host inflammatory cell infiltrates in tumor, and the induction of tumor-specific immunity. The ultimate goal of this research is to identify candidate strategies for clinical development, alone or in combination with tumor vaccines. We have made significant progress toward achieving these goals. lnterleukin-2 (IL-2) has been biotinylated, and its biological properties have been thoroughly characterized. We have obtained a streptavidin-conjugated monoclonal antibody that recognized the Ep-CAM tumor antigen that is frequently overexpressed in breast cancer specimens. The biodistribution properties of the antibody - streptavidin conjugate and of the conjugate admixed with biotinylated IL-2 have been characterized, and pretargeting therapy studies are about to commence
Ovarian Cancer Prevention Program( )

4 editions published between 1999 and 2002 in English and held by 0 WorldCat member libraries worldwide

The goals of this research are to develop interdisciplinary studies of the etiology, biology and prevention of ovarian cancer. Project I, Ovarian Cancer Consortium has registered 687 participants including 234 patients representing 320 families. The Core Laboratory has collected, processed and banked biospecimens from 496 subjects. Project II, Facilitating Decision Marking About Prophylactic Oophorectomy: baseline data on 80 women are available for preliminary analysis; 15 women, (19%) made a decision about having prophylactic oophorectomy while 66 women (76%) have not made a decision, and 4 women (5%) did not answer the questionnaire. Fifteen women said they would likely have a prophylactic oophorectomy in the near future. Project II!, Phase II Chemoprevention Study of Ovarian Cancer: this placebo-controlled randomized protocol using 4HPR has been written, approved by the Dept. of Defense, the National Cancer Institute Chemoprevention Branch, and the FDA. The Gynecologic Oncology Group has implemented the study throughout the country for interested gynecologic oncologists. Data entry and quality control systems have been established and 14 different case report forms are finalized. Seven women have signed consent forms, 6 were enrolled in the Ovarian Tissue Donation Portion of the study, and one has randomized to treatment and completed her prophylactic oophorectomy in March 2000
Targeting Breast Cancer With Anti HER2/neu Diabodies( )

5 editions published between 1999 and 2003 in English and held by 0 WorldCat member libraries worldwide

The objective of this proposal is to develop new therapeutic reagents for breast cancer using diabody-based molecules with affinity for HER2/neu for the radioimmunotherapy (RAIT) of breast cancer. The first Technical Objective (T.O.) has focused on the optimization of the production of the selected diabody and the identification of the optimal radionuclide and labeling strategy for diabody-based RAIT. This T.O. also has involved an investigation into the impact on diabody targeting of factors likely to be encountered in a clinical setting. These include the degree of antigen density, the route (i.v. bolus or continuous infusion) and frequency of administration, the presence of disseminated disease, and the effect of antigen expression on normal tissues. Completion of these experiments has set the stage for proceeding to the clinical evaluation of diabody-based targeting of breast cancer in our second Technical Objective. Current experiments demonstrate the feasibility and efficacy of alpha particle based radioimmunotherapy wherein the radionuclide is conjugated to a chelated diabody molecule. The clinical component of this proposal will entail a Phase I radioimmunoimaging and radioimmunoguided surgery trial to elicit information on the dosimetry, specificity and tumor penetration properties of radiolabeled C6.5 diabody, and will assess the RAIT potential of this molecule
Facilitating Treatment Decision Making, Adjustment and Coping in Men Newly Diagnosed With Prostate Cancer( )

4 editions published between 2001 and 2004 in English and held by 0 WorldCat member libraries worldwide

This study evaluated the efficacy of a patient-spouse centered cognitive-affective counseling session (CARE: cognitive affective reactions and expectations), to facilitate treatment decision-making for localized prostate cancer (PrCa). CARE identified treatment-related values and goals and focused on improving knowledge about treatment options. A time and attention matched General Health Information (GHI) session provided nutrition information. Couples (N=300) were enrolled after diagnosis with PrCa, but before a definite treatment decision was made. Data were assessed separately for patients and spouses at baseline, at 6-months, and at 12 months post intervention. Both sessions were well accepted among participants. The goal of CARE to facilitate treatment decision making was best achieved for spouses and among those patient/partners who chose a non-invasive treatment option. Partners were more distressed about the treatment decision compared to patients, especially in the CARE condition and when considering invasive procedures. We interpret this result as an indication that participants in CARE processed the relevant information and that momentarily higher levels of distress were the "cost" of such processing. At 6-mo this effect disappears, underscoring its temporal nature. The results demonstrate the usefulness of integrating a brief counseling session into the decision-making process, and that increases in perceived difficulty of decision-making are short-term
BRCC36, a Novel Subunit of a BRCA1 E3 Ubiquitin Ligasa Complex: Candidates for BRCA3( )

4 editions published between 2005 and 2008 in English and held by 0 WorldCat member libraries worldwide

Breast cancer is a genetically heterogeneous disease, and multiple genes remain to be identified among BRCAl and BRCA2 mutation-negative breast cancer-prone families. We believe that a valid approach to identify genetic factors that contribute to breast cancer risk is to evaluate genes coding for proteins that interact with BRCAl in a multiple protein complex. We have recently found one such candidate, referred to as BRCC36. We have reported a profound increase in BRCC36 expression in breast tumors. Furthermore, our studies have defined BRCC36 as a direct regulator of BRCA1 activation and nuclear foci formation in response to IR in a number of breast cancer cell lines. Our results have found that down-regulation of BRCC36 expression impairs homologous recombination repair (HRR) . Therefore, our data suggest that DNA repair pathway activated in response to IR and appears to sensitize breast cancer cells to IR-induced apoptosis. Importantly, we found that BRCC36 mutated in the germline of a cancer-prone family and may increase the risk of developing breast cancer. Overall, aberrant expression or mutation of BRCC36 genes in breast tumors may lead to disruption of the normal function of BRCAl and contribute to the development of breast cancer
Evaluation of Feasibility for a Case-Control Study of Adrenal Androgen Production in Postmenopausal Women With Breast Cancer( )

4 editions published between 2003 and 2006 in English and held by 0 WorldCat member libraries worldwide

Postmenopausal women with elevated serum estrogens and androgens are at an increased risk of breast cancer. Dehydroepiandrosterone sulfate (DHEAS) is secreted only by the adrenals, and elevated serum DHEAS levels in postmenopausal women who develop breast cancer suggest increased adrenal androgen production. The objective of the pilot study is to evaluate the feasibility of conducting a case-control study that uses adrenocorticotropic hormone (ACTH) stimulation tests to determine if postmenopausal women who develop breast cancer secrete more adrenal androgens, which are converted to estrogens in peripheral tissues, in response to ACTH stimulation compared to unaffected women. Hypotheses to be tested in the full-scale study are: 1) greater adrenal responsiveness to ACTH contributes to elevated serum concentrations of androgens and estrogens in postmenopausal women who develop breast cancer; and 2) increased adrenal androgen production in postmenopausal women with breast cancer is related to increased enzyme activity at a specific step in steroidogenesis rather than to generalized enhancement of adrenal androgen production. Cellular immune function also has been hypothesized to play a role in breast cancer etiology, and cortisol, which is another hormone that is secreted by the adrenals, is immunosuppressive (i.e., causes significant decreases in numbers and percentages of lymphocytes in the blood). At no additional cost to DOD we are also collecting preliminary data to begin to address the hypothesis that greater adrenal responsiveness to ACTH contributes to greater immunosuppression in postmenopausal women who develop breast cancer
Reversal of Multidrug Resistance in Breast Cancer( )

4 editions published between 1994 and 1997 in English and held by 0 WorldCat member libraries worldwide

Our data show that MDR1 gene expression is important in breast cancer resistance. The role of the MDR1 gene in breast cancer treatment will be further defined by sequentially determining MDR1 gene expression pre and post treatment with doxorubicin in the context of three prospective clinical trials. In addition, this study will allow a correlation of MDR1 gene expression and clinical outcome. To determine what level of MDR1 gene expression is clinically significant, various molecular methods of determining MDR1 gene expression, including immunohistochemistry and quantitative reverse transcription followed by polymerase chain reaction, will be evaluated. MDR can be reversed in vitro and we will test this hypothesis in a Phase I study of Cyclosporine A and quinine as MDR reversers of Vinblastine resistance. Together these studies will address the major goal of circumventing drug resistance in breast cancer. When the data of the MDR1 gene expression in breast cancer specimens from this proposal are available, clinical trials incorporating the modulators of MDR, Cyclosporine and quinine, will be designed for breast cancer as well. An alteration in drug efflux potentially may have an impact on response to chemotherapy and may result in improved survival for breast cancer patients. During the period between March 15, 1993 and March 14, 1997, we have outfitted our laboratory with staff, equipment, supplies and reagents, have been performing control experiments and have been pursuing activation of the various clinical trials to support this project. We now have some preliminary data on the expression of MDR1 and MRP (Multidrug resistant associated protein) in breast cancer specimens and normal adjacent breast tissue. Further follow-up of these patients is needed to determine the clinical significance of expression of these drug resistance genes
Cognitive-Affective Predictors of the Uptake of and Sustained Adherence to Lymphedema Symptom Minimization Practices in Breast Cancer Survivors( )

5 editions published between 2003 and 2007 in English and held by 0 WorldCat member libraries worldwide

Approximately 20-30% of women develop lymphedema (LE) following breast cancer treatment; this condition has been associated with psychological distress and diminished quality of life. Effective symptom management requires that women not only recognize early signs of this condition, but that they uptake and maintain precautionary practices over their lifetime. Yet, the limited data available indicate that knowledge and use of symptom minimization precautions are poor, particularly over time. Unfortunately, little is known about how breast cancer survivors perceive their LE risk status, and the cognitive- affective factors that promote the uptake of, and adherence to, LE symptom minimization precautions. Further, the moderating role of individual differences in attentional style has not been explored. Guided by the Cognitive-Social Health Information Processing (C- SHIP) model, we will conduct a longitudinal study, to assess the barriers and facilitators associated with knowledge about, and adherence to, LE symptom-minimization practices among breast cancer survivors currently unaffected by LE. We will explore the mediating role of cognitive-affective variables, and the moderating role of attentional style, on knowledge, uptake and adherence over time. Toward this end, we will survey levels of knowledge, and the practice of symptom minimization precautions at baseline, and again at 6-, and 12- month follow-up
Quality of Life After Prophylactic Oophorectomy( )

5 editions published between 2001 and 2005 in English and held by 0 WorldCat member libraries worldwide

While an increasing number of women at risk for ovarian cancer are being identified through awareness efforts and risk assessment programs, a gap still exists in the known psychological and physical sequelae of preventive surgery options offered to these women. To meet the needs of women seeking information about the effects of prophylactic oophorectomy, this pilot study will provide significant information on the broader quality of life issues and physical changes following surgery. In order to make informed decisions about their choices, women considering prophylactic oophorectomy need scientific data on the hormonal and other physical consequences of surgery, and on the potential alterations in their emotional and social well being. They also need the opportunity to choose from an array of coping strategies to manage their health decisions. Studying multidimensional quality of life issues will contribute to the knowledge base about the short and long-term effects on physical, emotional, cognitive, sexual and social functioning following oophorectomy and will contribute to the development of optimum medical and alternative therapy strategies to deal with post-surgical changes. As important, it will also identify issues and needs faced by women who make the choice not to undergo surgery
Pharmacogenetic Factors Contributing to Variation in Response to Tamoxifen and Raloxifene( )

4 editions published between 2001 and 2004 in English and held by 0 WorldCat member libraries worldwide

The purpose of these studies is to elucidate the pharmacogenetic factors that contribute to variation in human response to tamoxifen (TAM) and raloxifene (RAL). We had previously identified and partially characterized common genetic polymorphisms in two human drug-metabolizing genes, SULT1A1 and UGT1A1. We hypothesized that these polymorphisms contributed to variation in TAM or RAL metabolism. These studies were divided into three aims with the purpose of: (1) biochemically characterizing the contribution of these enzymes to the metabolism of TAM and RAL; (2) developing cell model systems to study allele-specific differences in cellular response to these molecules and; (3) perform a clinical pharmacogenetic study to evaluate the association of common genetic polymorphisms in drug metabolizing genes with variable clinical response to TAM. Thus far we have determined that SULT1A1 and UGT1A6 contributed to the inactivation of 4-hydroxytamoxifen (OHT), the active metabolite of TAM, and that a separate enzyme, UGT1A9 catalyzed the glucuronidation of RAL. We established MCF-7 breast cancer cell lines stably expressing the wildtype and variant SULT1A1 alleles and have measured allele-specific differences in the response of these cells to estrogens and OHT. These studies suggest that pharmacogenetic factors might contribute to variable cellular response to antiestrogens
Tailored Communication to Enhance Adaption Across the Breast Cancer Spectrum( )

6 editions published between 2002 and 2007 in English and held by 0 WorldCat member libraries worldwide

The Behavioral Center of Excellence (BCE) in Breast Cancer was established to provide a comprehensive, multi disciplinary approach for studying the process of, and methods for facilitating, successful adaptation in the context of breast cancer risk, treatment, and recovery. The four ongoing studies are derived from and integrated by a unifying theoretical framework, and are supported by four core facilities (i.e., Administrative, Communication, Genetic Testing and Bioinformatics Core). The four projects are: I) development of an intervention to promote utilization of breast cancer risk assessment programs and adherence to screening recommendations among underserved African-American women; 2) use of a "teachable moment" and tailored communication materials to promote utilization of risk assessment and adherence to screening among daughters of diagnosed breast cancer patients; 3) the promotion of psychological and physical adaptation among breast cancer patients at the completion of active treatment(i.e., during the re-entry phase); 4) promotion of psychological adaptation among metastatic breast cancer patients. The overarching goal is to develop theoretically guided, tailored, and transportable breast cancer communications to enhance screening adherence, decision-making, and quality of life across the spectrum of disease (i.e., from risk through treatment to survivorship)
The Nuclear Death Domain Protein p84N5; a Candidate Breast Cancer Susceptibility Gene( )

4 editions published between 2004 and 2007 in English and held by 0 WorldCat member libraries worldwide

Besides family history of cancer and an individual's age, no single etiologic factor can identify women at an increased risk for the disease. Approximately 10% of all cases of breast cancer exhibit a familial pattern of incidence. Efforts to identify the genetic basis of familial breast cancer reached fruition some years ago, when the breast-cancer susceptibility genes, BRCAl and BRCA2 were identified. However, recent studies have suggested that mutations in these genes are associated with a smaller number (20 to 60%) of hereditary breast cancer families than originally estimated, especially in studies that have been based on population- based family materials. Several groups including ours are searching for additional breast cancer susceptibility genes using whole genome scanning approaches, but the success of many of these approaches depend on the underlying heterogeneity of the remaining cancer susceptibility loci. The failure to date to identify additional breast cancer susceptibility genes associated with a high risk of disease suggests that more than one may exist. We have taken the approach that the next BRCA genes will be those that encode for proteins whose functions are linked to important cell regulatory pathways. We have recently found one such candidate BRCA3 protein, referred to as p84N5
moreShow More Titles
fewerShow Fewer Titles
Audience Level
Audience Level
  Kids General Special  
Audience level: 0.58 (from 0.46 for Scientific ... to 1.00 for Pharmacoge ...)

Alternative Names
English (81)